Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017)
AST.WS
AST.WS was delisted on the 26th of September, 2017.
38 hedge funds and large institutions have $142K invested in Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) in 2016 Q2 according to their latest regulatory filings, with 38 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$171K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$95.3K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$46.8K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$15.4K |
| 5 |
Goldman Sachs
New York
|
+$9.65K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| – | +$30 | +58 | New |
|
27
Creative Planning
Overland Park,
Kansas
| – | +$58 | +112 | New |
|
|
LTFS
28
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | +$70 | +134 | New |
|
29
US Bancorp
Minneapolis,
Minnesota
| – | +$71 | +137 | New |
|
30
Fifth Third Bancorp
Cincinnati,
Ohio
| – | +$86 | +165 | New |
|
31
Bank of America
Charlotte,
North Carolina
| – | +$88 | +169 | New |
|
|
IA
32
IFP Advisors
Tampa,
Florida
| – | +$136 | +262 | New |
|
|
TCIM
33
TIAA CREF Investment Management
New York
| – | +$177 | +339 | New |
|
34
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | +$256 | +492 | New |
|
35
UBS Group
Zurich,
Switzerland
| – | +$617 | +1,184 | New |
|
36
Bank of Montreal
Toronto,
Ontario, Canada
| – | +$830 | +1,594 | New |
|
37
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$1K | +1,920 | New |
|
38
New York State Common Retirement Fund
Albany,
New York
| – | +$1K | +1,920 | New |
|
AST.WS Hedge Fund Activity: Q2 2016 in Review
38 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) (AST.WS) for Q2 2016, worth a combined $142K.
Buyers outnumbered sellers: 38 funds opened new AST.WS positions and 0 closed out — a net gain of 38 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Broadwood Capital, opening a new position worth an estimated $171K.
- 38 institutional investors held Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) (AST.WS) as of Q2 2016, up from 0 in Q1 2016.
- Funds reported $142K of Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) stock for Q2 2016.
- 38 funds opened new Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) positions in Q2 2016 and 0 closed out, a net change of +38 holders.
- The largest Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) buyer in Q2 2016 was Broadwood Capital, an estimated $171K added.
Based on aggregated 13F filings for Q2 2016.